Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
Vaso-occlusive crisis in Sickle cell disease might alter myocardial function through micro vascular obstruction.
1 France site
> 18 Years
As safety information pertaining to the long-term use of HU remains incomplete in spite of the first safety study (ESCORT-HU), an extension of the latter is proposed.
61 France site
5 Germany sites
4 French Guiana sites
4 Italy sites
2 Guadeloupe sites
2 Martinique sites
1 Greece site
> 2 Years
Sickle cell disease (SCD) is an inherited blood disorder.
1 France site
> 18 Years
Sickle cell disease is the most common single-gene disease in the world.
1 France site
20 Years - 40 Years
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
49 United States sites
5 France sites
5 Spain sites
4 Greece sites
4 Italy sites
4 United Kingdom sites
3 Canada sites
2 Lebanon sites
2 Germany sites
12 Years - 65 Years
Phase 2/Phase 3
The purpose of this phase IIb, international, multicentre, double-blind, randomised, placebo-controlled study is to determine the effect of hydroxycarbamide on albuminuria after 6 months of treatment in SCD adult patients.
16 France sites
1 Côte D'Ivoire site
1 Guadeloupe site
1 Mali site
1 Martinique site
1 Senegal site
> 18 Years
HbSS
Phase 2
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.
18 United States sites
1 United Kingdom site
1 France site
> 18 Years
Phase 3
This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease.
17 United States sites
5 Nigeria sites
4 Egypt sites
4 Kenya sites
4 United Kingdom sites
3 Italy sites
2 Ghana sites
2 Oman sites
2 Saudi Arabia sites
1 France site
2 Years - 14 Years
SCA
Phase 3
Three methods are actually used in newborn screening for sickle cell disease (SCD) in France: isoelectric focusing, high performance liquid chromatography and capillary electrophoresis.
3 France sites
1 Day - 27 Days Years
Many patients with Sickle Cell Disease (SCD) may develop Acute Chest Syndrome (ACS).
1 France site
> 18 Years
Not Applicable
